Ibogaine acts at the nicotinic acetylcholine receptor to inhibit catecholamine release

Brain Research

Volumn 797, Issue 1, 1998, Pages 173-180

  Mah, Stephanie J ^a   Tang, Yuming ^a   Liauw, Pauline E ^a   Nagel, Jean E ^a   Schneider, Allan S ^a  

^a ALBANY MEDICAL COLLEGE   (United States)

Author keywords

Anti addictive agent; Catecholamine release; Chromaffin cell; Ibogaine mechanism; Nicotinic acetylcholine receptor

Indexed keywords

BINALTORPHIMINE; IBOGAINE; KAPPA OPIATE RECEPTOR; NALTREXONE; NICOTINIC RECEPTOR; VERATRIDINE;

ADDICTION; ANIMAL CELL; ARTICLE; CATECHOLAMINE RELEASE; CHROMAFFIN CELL; MEMBRANE DEPOLARIZATION; NONHUMAN; PRIORITY JOURNAL; RECEPTOR AFFINITY; RECEPTOR BINDING;

ANIMALS; CATECHOLAMINES; CATTLE; CELLS, CULTURED; CHROMAFFIN CELLS; DIMETHYLPHENYLPIPERAZINIUM IODIDE; DOSE-RESPONSE RELATIONSHIP, DRUG; HALLUCINOGENS; IBOGAINE; NICOTINE; NICOTINIC AGONISTS; RECEPTORS, NICOTINIC; TETRODOTOXIN;

EID: 0032557960     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-8993(98)00207-8     Document Type: Article

References (48)

1. Badio B., Padgett W.L., Daly J.W. Ibogaine: a potent noncompetitive blocker of ganglionic/neuronal nicotinic receptors. Mol. Pharmacol. 51:1997;1-5.
2. Benwell M.E.M., Holtom P.E., Moran R.J., Balfour D.J.K. Neurochemical and behavioural interactions between ibogaine and nicotine in the rat. Br. J. Pharmacol. 117:1996;743-749.
3. Bowen W.D., Vilner B.J., Williams W., Bertha C.M., Kuehne M.E., Jacobson A.E. Ibogaine and its congers are sigma 2 receptor-selective ligands with moderate affinity. Eur. J. Pharmacol. 279:1995;R1-3.
4. Brandt B.L., Hagiwara S., Kidokoro Y., Miyazaki S. Action potentials in rat chromaffin cells and effects of acetylcholine. J. Physiol. 263:1976;417-439.
5. Briggs C.A., McKenna D.G. Effect of MK-801 at the human α7 nicotinic acetylcholine receptor. Neuropharmacology. 35:1996;407-414.
6. Bullock A.E., Barke K.M., Schneider A.S. Nicotine tolerance in chromaffin cell cultures: acute and chronic exposure to smoking-related nicotine doses. J. Neurochem. 62:1994;1863-1869.
7. 2+-uptake into cultured bovine adrenal medullary cells. Biochem. Pharmacol. 41:1991;715-722.
8. Bunn S.J., Marley P.D., Livett B.G. The distribution of opioid binding subtypes in the bovine adrenal medulla. Neurosci. 27:1988;1081-1094.
9. Campos-Caro A., Smillie F.I., Dominguez del Toro E., Rovira J.C., Vicente-Agullo F., Chapuli J., Juiz J.M., Sala S., Sala F., Ballesta J.J., Criado M. Neuronal nicotinic receptors on bovine chromaffin cells: cloning, expression, and genomic organization of receptor subunits. J. Neurochem. 68:1997;488-497.
10. Cappendijk S.L.T., Dzoljic M.R. Inhibitory effects of ibogaine on cocaine self-administration in rats. Eur. J. Pharmacol. 241:1994;261-265.
11. Clarke P.B. Nicotinic receptors in mammalian brain: localization and relation to cholinergic innervation. Prog. Brain Res. 98:1993;77-83.
12. Codd E.E. High affinity ibogaine binding to a mu opioid agonist site. Life Sci. 57:1995;315-320.
13. Corrigall W.A., Coen K.M., Adamson K.L. Self-administered nicotine activates the mesolimbic dopamine system through the ventral tegmental area. Brain Res. 653:1994;278-284.
14. Criado M., Alamo L., Navarro A. Primary structure of an agonist binding subunit of the nicotinic acetylcholine receptor from bovine adrenal chromaffin cells. Neurochem. Res. 17:1992;281-287.
15. Deecher D.C., Teitler M., Soderlund D.M., Bormann W.G., Kuehne M.E., Glick S.D. Mechanisms of action of ibogaine and harmaline congers based on radioligand binding studies. Brain Res. 571:1992;242-247.
16. Di Chiara G., Imperato A. Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats. Proc. Natl. Acad. Sci. USA. 85:1988;5274-5278.
17. Dworkin S.I., Gleeson S., Meloni D., Koves T.R., Martin T.J. Effects of ibogaine on responding maintained by food, cocaine and heroin reinforcement in rats. Psychopharmacology. 117:1995;257-261.
18. Glick S.D., Rossman K., Steindorf S., Maisonneuve I.M., Carlson J.N. Effects and after effects of ibogaine on morphine self-administration in rats. Eur. J. Pharmacol. 195:1991;341-345.
19. Glick S.D., Kuehne M.E., Raucci J., Wilson T.E., Larson D., Keller R.W., Carlson J.N. Effects of iboga alkaloids on morphine and cocaine self-administration in rats: relationship to tremorigenic effects and to effects on dopamine release in nucleus accumbens and striatum. Brain Res. 657:1994;14-22.
20. Hough L.B., Pearl S.M., Glick S.D. Tissue distribution of ibogaine after intraperitoneal and subcutaneous administration. Life Sci. 58:1996;PL119-122.
21. Kao L.S., Schneider A.S. Calcium mobilization and catecholamine secretion in adrenal chromaffin cell. A Quin-2 fluorescence study. J. Biol. Chem. 261:1986;4881-4888.
22. + (GIRK) channel in Xenopus oocytes. Br. J. Pharmacol. 119:1996;73-80.
23. Koob G.F., Bloom F.E. Cellular and molecular mechanisms of drug dependence. Science. 242:1988;715-723.
24. Kumakura K., Karoum F., Guidotti A., Costa E. Modulation of nicotinic receptors by opiate receptor agonists in cultured adrenal chromaffin cells. Nature. 283:1980;489-492.
25. H.S. Lotsof, Rapid method for interrupting the narcotic addiction syndrome, US Patent No. 4,499,096 (1985).
26. H.S. Lotsof, Rapid method for interrupting the cocaine and amphetamine abuse syndrome, US Patent No. 4,587,243 (1986).
27. H.S. Lotsof, Rapid method for attenuating the alcohol dependency syndrome. US Patent No. 4,587,523 (1989).
28. H.S. Lotsof, Rapid method for interrupting or attenuating the nicotine/tobacco dependency syndrome, US Patent No. 5,026,697 (1991).
29. 2 receptors. Life Sci. 57:1995;57-62.
30. Maisonneuve I.M., Glick S.D. Interactions between ibogaine and cocaine in rats: in vivo microdialysis and motor behaviour. Eur. J. Pharmacol. 212:1992;263-266.
31. Maisonneuve I.M., Rossman K.L., Keller R.W. Jr., Glick S.D. Acute and prolonged effects of ibogaine on brain dopamine metabolism and morphine-induced locomotor activity in rats. Brain Res. 575:1992;69-73.
32. Maisonneuve I.M., Mann G.L., Deibel C.R., Glick S.D. Ibogaine and the dopaminergic response to nicotine. Psychopharm. 129:1997;249-256.
33. McGehee D.S., Heath M.J., Gelber S., Devay P., Role L.W. Nicotine enhancement of fast excitatory synaptic transmission in CNS by presynaptic receptors. Science. 269:1995;1692-1696.
34. 2+ uptake and catecholamine secretion from adrenal chromaffin cells by taxol and vinblastine. J. Pharmacol. Exp. Ther. 231:1984;102-108.
35. McKay D.B., Aronstam R.S., Schneider A.S. Interactions of microtubule-active agents with nicotinic acetylcholine receptors. Relationship to their inhibition of catecholamine secretion by adrenal chromaffin cells. Mol. Pharmacol. 28:1985;10-16.
36. Nisell M., Nomikos G.G., Svensson T.H. Infusion of nicotine in the ventral tegmental area or the nucleus accumbens of the rat differentially affects accumbal dopamine release. Pharmacol. Toxicol. 75:1994;348-352.
37. Nisell M., Nomikos G.G., Svensson T.H. Nicotine dependence, midbrain dopamine systems and psychiatric disorders. Pharmacol Toxicol. 76:1995;157-162.
38. Paul I.A., Basile A.S., Rojas E., Youdim M.B.H., DeCosta B., Skolnick P., Pollard H.B., Kuijpers G.A. Sigma receptors modulate nicotinic receptor function in adrenal chromaffin cells. FASEB J. 7:1993;1171-1178.
39. 3H]MK-801 binding to the NMDA receptor complex. Psychopharmacol. 114:1994;672-674.
40. Popik P., Layer R.T., Skolnick P. 100 years of ibogaine: neurochemical and pharmacological actions of a putative anti-addictive drug. Pharmacol. Rev. 47:1995;235-253.
41. Ramoa A.S., Alkondon M., Arcava Y., Irons J., Lunt G.G., Deshpande S.S., Wonnacott S., Aronstam R.S., Albuquerque E.X. The anticonvulsant MK-801 interacts with peripheral and central nicotinic acetylcholine receptor ion channels. J. Pharmacol. Exp. Ther. 254:1990;71-82.
42. Schneider A.S., Nagel J.E., Mah S.J. Ibogaine selectively inhibits nicotinic receptor-mediated catecholamine release. Eur. J. Pharmacol. 317:1996;R1-R2.
43. Schneider A.S., Mah S.J., Liauw P.E., Tang Y.M., Nagel J.E. Ibogaine and kappa opioid agonists have a selective inhibitory action on nicotinic receptor-mediated catecholamine release. Soc. Neurosci. Abst. 22:1996;70.13.
44. Sershen H., Hashim A., Harsing L., Lajtha A. Ibogaine antagonizes cocaine-induced locomotor stimulation in mice. Life Sci. 50:1992;1079-1086.
45. 3H]dopamine. Brain Res. Bull. 40:1996;63-67.
46. Sweetnam P.M., Lancaster J., Snowman A., Collins J.L., Perschke S., Bauer C., Ferkany J. Receptor binding profile suggests multiple mechanisma of action are responsible for ibogaines's putative anti-addictive activity. Psychopharmacology. 118:1995;369-376.
47. Yoshida M., Yokoo H., Tanaka T., Mizuguchi K., Emotot H., Ishii H., Tanaka M. Facilitatory modulation of mesolimbic dopamine neuronal activity by a mu-opioid agonist and nicotine as examined with in vivo microdialysis. Brain Res. 624:1993;277-280.
48. Zetler G., Singbarth G., Schlosser L. Cerebral pharmacokinetics of tremor-macokinetics of tremor-producing harmal and iboga alkaloids. Pharmacol. 7:1972;237-248.